Recent News

• 08.26.2025 - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
• 08.26.2025 - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
• 07.23.2025 - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
• 07.23.2025 - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
• 07.17.2025 - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
• 07.17.2025 - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
• 06.17.2025 - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
• 06.17.2025 - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
• 05.27.2025 - Stifel 2025 Virtual Ophthalmology Forum
• 05.21.2025 - Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - DEF 14A Other definitive proxy statements
• 07.25.2025 - PRE 14A Other preliminary proxy statements
• 07.17.2025 - 8-K Current report
• 07.17.2025 - EX-99.1 EX-99.1
• 05.30.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - S-8 Securities to be offered to employees in employee benefit plans